Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI343 + Sintilimab + Chemotherapy in Advanced Gastric/GEJ Adenocarcinoma
NCT07025889Phase 2Recruiting
- Sponsor
- Ruijin Hospital
- Start
- Jun 2025
- Primary completion
- Jul 2027
- Countries
- 1
01
Overview
A Phase 2 trial of arcotatug tavatecan in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Ruijin Hospital. Started Jun 2025; status: recruiting.
02
Drugs
arcotatug tavatecan
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT07025889.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07025889.